High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation

Guidelines regarding treatment for autoimmune hepatitis (AIH) favour two strategies for azathioprine (AZA) introduction: concurrent with steroids at induction or delayed by 2‐4 weeks. The safety and efficacy of both strategies have been unexplored.

[1]  T. Gevers,et al.  Clinical management of autoimmune hepatitis , 2019, United European gastroenterology journal.

[2]  C. Mulder,et al.  Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands , 2014, Scandinavian journal of gastroenterology.

[3]  M. Heneghan,et al.  Mortality and the risk of malignancy in autoimmune liver diseases: A population‐based study in Canterbury, New Zealand , 2013, Hepatology.

[4]  L. Lennard,et al.  Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis , 2012, Hepatology.

[5]  R. Gearry,et al.  Mortality and the risk of malignancy in autoimmune liver diseases: A population‐based study in Canterbury, New Zealand , 2012, Hepatology.

[6]  M. V. van Oijen,et al.  Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. , 2010, Journal of hepatology.

[7]  M. Manns,et al.  Diagnosis and management of autoimmune hepatitis , 2010, Hepatology.

[8]  Y. Zen,et al.  Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. , 2010, Journal of hepatology.

[9]  K. Boberg,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Simplified Criteria for the Diagnosis of Autoimmune Hepatitis , 2008 .

[10]  K. Saeian,et al.  Increased Rates of Early Adverse Reaction to Azathioprine in Patients with Crohn's Disease Compared to Autoimmune Hepatitis: A Tertiary Referral Center Experience , 2005, The American Journal of Gastroenterology.

[11]  A. von Eckardstein,et al.  Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis , 2004, European journal of gastroenterology & hepatology.

[12]  S. Emre,et al.  Azathioprine Metabolite Measurements in the Treatment of Autoimmune Hepatitis in Pediatric Patients: A Preliminary Report , 2002, Journal of pediatric gastroenterology and nutrition.

[13]  G. Gerken,et al.  Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. , 2001, Zeitschrift fur Gastroenterologie.

[14]  L. Burgart,et al.  Azathioprine-induced lymphoma manifesting as fulminant hepatic failure. , 1997, Mayo Clinic proceedings.

[15]  G. Bazzocchi,et al.  Acute pancreatitis after azathioprine treatment for ulcerative colitis. , 1996, The Italian journal of gastroenterology.

[16]  R. Williams,et al.  Azathioprine for long-term maintenance of remission in autoimmune hepatitis. , 1995, The New England journal of medicine.

[17]  Roger Williams,et al.  Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal , 1988, Hepatology.

[18]  L. van de Putte,et al.  Pancytopenia related to azathioprine in rheumatoid arthritis. , 1988, Annals of the rheumatic diseases.

[19]  B. Portmann,et al.  RANDOMISED CONTROLLED TRIAL OF AZATHIOPRINE WITHDRAWAL IN AUTOIMMUNE CHRONIC ACTIVE HEPATITIS , 1985, The Lancet.

[20]  W. Summerskill,et al.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. , 1975, Gut.

[21]  I. Mackay,et al.  TREATMENT OF ACTIVE CHRONIC HEPATITIS AND LUPOID HEPATITIS WITH 6-MERCAPTOPURINE AND AZOTHIOPRINE. , 1964, The Lancet.

[22]  J. Drenth.  EASL Clinical Practice Guidelines: Autoimmune hepatitis. , 2015, Journal of hepatology.

[23]  G. Mieli-Vergani,et al.  Autoimmune hepatitis. , 2011, Journal of hepatology.